Merck & CompanyvsZymeworks

MRK and ZYME stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$147.76

Value $365B

+0.55%
MRK's page

Merck & Company (MRK) has a market value of $365B and Zymeworks (ZYME) $1.8B. Over the last year, with dividends, MRK moved +66.3% and ZYME +35.5%. The P/E is 148.9 for MRK and 41.8 for ZYME. Dividend yield: MRK 2.30%, ZYME none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$365B

    ZYME$1.8B

    MRK is 202 times ZYME

  • Revenue, 12 months

    MRK$67.4B

    ZYME$266M

    MRK is 253 times ZYME

  • Net income, 12 months

    MRK$2.5B

    ZYME$43M

    MRK is 57 times ZYME

  • Operating margin

    MRK–

    ZYME16.6%

  • ROIC

    MRK3.9%

    ZYME16.0%

    12.1 points apart

  • P/E

    MRK148.9

    ZYME41.8

    MRK is 3.6 times ZYME

  • Dividend yield

    MRK2.3%

    ZYME0.0%

    2.3 points apart

  • 5-year return

    MRK+104.9%

    ZYME+30.2%

    74.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+104.9%

ZYME+30.2%

10020020222023202420252026
Returns by period
PeriodMRKWith dividendsZYMEWith dividends
1 year since November 12, 2025+66.3%Price +61.6%+35.5%Price +35.5%
3 years since November 13, 2023+58.0%+16.5% a yearPrice +44.2%+260.9%+53.4% a yearPrice +260.9%
5 years since November 12, 2021+104.9%+15.4% a yearPrice +75.9%+30.2%+5.4% a yearPrice +30.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyZYMEZymeworks

Valuation

MRKZYME
Valuation
Price$147.76$26.24
Market value$365B$1.8B
Enterprise value (EV)$409B$2.0B
P/E148.941.8
P/E, 5-year median14.8–
P/B8.17.0
EV/EBIT86.046.4
Free cash flow yield4.0%–

Results and growth

MRKZYME
Results and growth
Revenue, 12 months$67.4B$266M
Net income, 12 months$2.5B$43M
Free cash flow, 12 months$14.7B-$113M
Earnings per share, 12 months$0.98$0.63
Revenue growth, year on year1.3%38.9%
Revenue growth a year, past+9.4%over 5 years+22.2%over 5 years
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKZYME
Margins and returns on capital
Gross margin71.8%–
Operating margin–16.6%
Net margin3.6%16.3%
ROIC3.9%16.0%
ROE5.2%19.9%

Balance sheet

MRKZYME
Balance sheet
Cash$9.7B$100M
Total debt$53.8B$392M
Net debt / EBITDA5.75.0
Interest cover2.4×–

Dividends and buybacks

MRKZYME
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.4%2.3%
Shareholder yield3.7%2.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or ZYME

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Zymeworks?

By market value, Merck & Company ($365B) is about 201.7 times Zymeworks ($1.8B), at today's prices.

How did MRK and ZYME stock do over the last 5 years?

Since November 12, 2021, MRK's price moved +75.9% and ZYME's +30.2%. With dividends: MRK +104.9% (+15.4% a year), ZYME +30.2% (+5.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or ZYME?

The dividend yield at today's price is 2.30% for Merck & Company and none for Zymeworks. Over the last twelve months they paid $3.40 and – per share.

What is the P/E of MRK and ZYME?

At today's price, the P/E is 148.9 for MRK and 41.8 for ZYME. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Merck & Company or Zymeworks?

Over the last twelve months, the net margin was 3.6% for Merck & Company and 16.3% for Zymeworks, and the operating margin – and 16.6%. Revenue was $67.4B and $266M.

Which is the better investment, Merck & Company or Zymeworks?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.